Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9203949 | 0.87 | GSR (0.37) | GSRCYP2D6KMT2AFBP1SRC | |
| SCHEMBL10976703 | 0.86 | GSR (0.39) | GSRCYP2D6KMT2AFBP1SRC | |
| SCHEMBL286963 | 0.85 | GSR (0.43) | GSRCYP2D6KMT2ASRCLMNA | |
| SCHEMBL22323630 | 0.85 | GSR (0.43) | GSRCYP2D6KMT2ASRCLMNA | |
| SCHEMBL5932816 | 0.84 | GSR (0.42) | GSRCYP2D6KMT2ASRCLMNA | |
| SCHEMBL10517386 | 0.83 | GSR (0.39) | GSRCYP2D6KMT2ASRCSMN1; SMN2 | |
| SCHEMBL5932183 | 0.82 | GSR (0.41) | GSRCYP2D6KMT2ASRCLMNA | |
| SCHEMBL3299147 | 0.82 | ALDH1A1 (0.49) | GSRCYP2D6KMT2AFBP1SRC | |
| SCHEMBL10640253 | 0.82 | GSR (0.41) | GSRCYP2D6KMT2ASRCLMNA | |
| SCHEMBL38107 | 0.82 | NPSR1 (0.43) | GSRCYP2D6SRCSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118420691-B | Avermectin derivative containing nitrobenzyl oxycarbonyl ester and its synthesis and use | 内蒙古嘉宝仕生物科技股份有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118420691-A | Avermectin derivative containing nitrobenzyl oxycarbonyl ester and its synthesis and use | 内蒙古嘉宝仕生物科技股份有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-109627236-A | Optoacoustic probe and the preparation method and application thereof for In vivo detection nitroreductase | 华南师范大学 | 2019-04-16 | — | — | CN | claimed |
| EP-0804413-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-11-05 | — | — | EP | claimed |
| WO-1996022277-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-25 | — | — | WO | claimed |
| US-12637495-B2 | De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals | MOLECULAR TEMPLATES, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260034230-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260028372-A1 | PROTEIN EXTRACTION, PROTEIN IDENTIFICATION, AND SPATIAL PROTEOMICS USING PHOTOCLEAVABLE ANCHOR IN SWELLABLE MATERIAL | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4619438-A2 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | Regeneron Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12365927-B2 | Engineered ketoreductase polypeptides | CODEXIS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4561636-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | Regeneron Pharmaceuticals, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250051474-A1 | ANTI-CD97 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | NEW YORK UNIVERSITY (US) | 2025-02-13 | — | — | US | disclosed |
| EP-0180252-A1 | Process of preparing azetidinone compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-05-07 | — | — | EP | disclosed |
| EP-0010316-B1 | 1-, 6- AND 2-SUBSTITUTED-1-CARBA-2-PENEM-3-CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | MERCK & CO. INC. (US) | 1983-10-05 | — | — | EP | disclosed |
| EP-0073451-A2 | Carbapenam compound and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-09 | — | — | EP | disclosed |
| EP-0054917-A2 | 6- and 4-Substituted-1-azabicyclo(3.2.0)heptan-3,7-dione-2-carboxylates | MERCK & CO. INC. (US) | 1982-06-30 | — | — | EP | disclosed |
| US-4309346-A | INTERMEDIATES FOR AMINO ACID DERIVATIVE ANTIBIOTICS | MERCK & CO., INC. (US) | 1982-01-05 | — | — | US | disclosed |
| US-4260627-A | 1-, 6- And 2-substituted-1-carba-2-penem-3-carboxylic acids | MERCK & CO., INC. (US) | 1981-04-07 | — | — | US | disclosed |
| EP-0010316-A1 | 1-, 6- and 2-substituted-1-carba-2-penem-3-carboxylic acids, process for preparing the same and pharmaceutical compositions containing the same | MERCK & CO. INC. (US) | 1980-04-30 | — | — | EP | disclosed |
| EP-0001628-A1 | 3-Substituted-6-substituted-7-oxo-1-azabicyclo (3.2.0)-hept-2-ene-2-carboxylic acid, its preparation and pharmaceutical compositions containing it | MERCK & CO. INC. (US) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637495-B2 | De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals | FCGRT, CD2, CD22 | GSR 4496/4885CYP2D6 4838/4885KMT2A 2666/4885 |
| US-20260034230-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | MUSK, TFRC, MYOF | GSR 1006/4885CYP2D6 2526/4885KMT2A 1699/4885 |
| US-20260028372-A1 | PROTEIN EXTRACTION, PROTEIN IDENTIFICATION, AND SPATIAL PROTEOMICS USING PHOTOCLEAVABLE ANCHOR IN SWELLABLE MATERIAL | SRMS, EPCAM, PTMS | GSR 3164/4885CYP2D6 3624/4885KMT2A 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.